有乳腺癌个人史的韩国女性筛查MRI阴性后的结局:对下一次MRI间隔的启示
回顾性分析993例有乳腺癌个人史且筛查乳腺MRI阴性的女性,中位随访31.8个月发现10例第二原发乳腺内癌(1%),其中80%为导管原位癌或淋巴结阴性T1期癌;仅1例淋巴结阴性T1mi癌在MRI后24个月内经乳腺X线检出。既往导管原位癌治疗与第二原发乳腺内癌相关(OR 3.73,95%CI 1.04-13.38,P=.04)。MRI的异常判读率低于乳腺X线和超声,特异度高于两者(P<.001)。
要点
- 筛查MRI阴性后第二原发乳腺内癌发生率低(1%),90%的后续癌在24个月以后检出。
- 第二原发乳腺内癌中80%为导管原位癌或淋巴结阴性T1期癌,40%仅由后续筛查MRI检出。
- 既往导管原位癌治疗与第二原发乳腺内癌相关(OR 3.73,95%CI 1.04-13.38,P=.04)。
核心结论
- 筛查MRI阴性后90%的后续癌在超过24个月的间隔检出,第二原发乳腺内癌率低(1%);MRI异常判读率低于乳腺X线和超声、特异度高于两者(P<.001)。
研究设计与样本
- 回顾性研究纳入2014年8月至2016年12月间连续993例有乳腺癌个人史、患病率筛查乳腺MRI阴性且随访至少12个月的女性(平均年龄53岁±10);比较筛查MRI、乳腺X线和超声的性能指标。
诊断标准与关键数值
- 第二原发乳腺内癌10例,中位间隔31.8个月(范围13.3-44.8个月),其中8例(80%)为导管原位癌或淋巴结阴性T1期癌。
临床应用与阅片要点
- 第二原发乳腺内癌中40%(4/10)仅由后续筛查MRI检出,该MRI在中位30.5个月后进行;仅1例淋巴结阴性T1mi(肿瘤≤1 mm)第二原发乳腺内癌在MRI后24个月内经乳腺X线检出。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There are limited data on outcomes following screening breast MRI in women with a personal history of breast cancer (PHBC). Purpose To investigate outcomes and factors associated with subsequent cancers following a negative screening MRI study in women with a PHBC. Materials and Methods Consecutive women with a PHBC and a negative prevalence screening breast MRI result between August 2014 and December 2016 were retrospectively identified. Inclusion criteria were prevalence screening MRI performed as part of routine surveillance protocol (1-3 years after treatment) and follow-up data for at least 12 months. The incidence and characteristics of subsequent cancers were reviewed. Logistic regression analysis was used to investigate associations between clinical-pathologic characteristics and subsequent cancers. Performance metrics were compared among screening MRI, mammography, and US. Results A total of 993 women (mean age ± standard deviation, 53 years ± 10) were evaluated. Ten second in-breast cancers (ie, ipsilateral or contralateral) occurred at a median interval of 31.8 months (range, 13.3-44.8 months) after MRI, of which eight (80%) were ductal carcinoma in situ (DCIS) or node-negative T1 cancers. Only one node-negative T1mi (tumor ≤1 mm) second in-breast cancer visible on a mammogram was detected within 24 months of MRI. Of second in-breast cancers, 40% (four of 10) were detected only at subsequent screening MRI, which was performed a median of 30.5 months after negative prevalence screening MRI. Ten local-regional recurrences occurred at a median interval of 16.9 months (range, 6-35 months). Previous treatment for DCIS was associated with second in-breast cancers (odds ratio, 3.73; 95% CI: 1.04, 13.38; P = .04). In 1048 women who underwent prevalence screening MRI (including all Breast Imaging Reporting and Data System categories), MRI showed a lower abnormal interpretation rate and higher specificity than mammography or US (P < .001 for all). Conclusion After a negative screening MRI result, 90% of subsequent cancers were detected at intervals longer than 24 months and there was a low second in-breast cancer rate (1%). © RSNA, 2021 Supplemental material is available for this article. See also the editorial by Chang in this issue.
引用
- Park VY, Kim MJ, Kim GR, et al. Outcomes Following Negative Screening MRI Results in Korean Women with a Personal History of Breast Cancer: Implications for the Next MRI Interval. Radiology. 2021. PMID: 34032514. doi:10.1148/radiol.2021204217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。